2022-RA-1473-ESGO Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in recurrent ovarian cancer – results of the Leuven HRD test
Proceedings article published in 2022 by
Liselore Loverix,
Ignace Vergote,
Adriaan Vanderstichele,
Pieter Busschaert,
Bram Boeckx,
Tom Venken,
Els van Nieuwenhuysen,
Thaïs Baert,
Sileny Han,
Patrick Neven,
Patrick Berteloot,
Siel Olbrecht,
Tina Laga,
Diether Lambrechts,
Toon van Gorp 
